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Non-surgical sterilizationImmunocontraceptive vaccines may be an alternative to surgical sterilization. Dual rabies vaccination
and dog population management is a helpful tool for rabies prevention. A synthetic gonadotropin-releas-
ing hormone (GnRH) peptide coupled to a carrier protein or T cell epitope is efﬁcacious in inducing
immunocontraception in a variety of mammals. However, virus-vectored GnRH recombinant vaccines
have advantages over the conjugation method. In a previous in vitro study, we were able to insert a
GnRH-coding sequence into the rabies virus (RABV) glycoprotein (G) gene, and the recombinant viruses
grew to high titers in cells. Here, we further focused on the RABV G in accepting various copy numbers of
GnRH. We demonstrated although RABV G protein with up to 4 copies of GnRH was well expressed, the
recombinant virus was recovered only when 2 copies of GnRH (20 amino acids) were incorporated into
the G, indicating a possible insertion limit in making a full infectious clone. The investigation provides
insight into the utility of RABV G as a carrier for small peptides and its suitability for vaccine studies. Fol-
lowing our previous study, we selected ERAg3p/2GnRH and tested the construct in mice. The vaccine
inducedP80% infertility after three doses without any adjuvant, in live (8 of 10 mice infertility) or inac-
tivated (13 of 14 mice infertility) formulations; while the pregnancy rate was 100% (10 of 10 mice) in the
controls. This initial success of immunocontraception in mice is promising, and we are now optimizing
the vaccine formulation by using adjuvants and exploring novel delivery methods to minimize the
dosage.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).Introduction
Global demonstration projects of canine rabies elimination re-
quire new tools [1]. Historical prevention of canine rabies relies
on vaccination and control of dog populations [2,3]. However, re-
sources are insufﬁcient for surgical sterilization in both developed
and developing countries. New non-surgical methods, such as
immunocontraception, may have added beneﬁt in the future
[4,5]. A vaccine that simultaneously protects against rabies and re-
duces fertility in both male and female dogs would be a major ad-
vance in rabies prevention. Synthetic gonadotropin-releasing
hormone (GnRH) peptides coupled to a carrier protein or T cell epi-
topes is efﬁcacious in inducing immunocontraception [6–9]. How-
ever, virus-vectored GnRH recombinants as self-replicative in cell
culture have the advantage over the conjugation method in vaccinemanufacturing. Here, we demonstrated the feasibility of rabies
virus (RABV)-vectored immunocontraception in a mouse model.
RABV is a compact negative-sense, single-stranded RNA virus. Ra-
bies vaccine is one of the oldest biologics used in humans for both
pre- and post-exposure prophylaxis [10]. Human rabies vaccina-
tion does not require adjuvant priming, and long-lasting immune
responses are documented [11–13]. More than a century of vacci-
nation practices and the safety record of rabies vaccines have led to
the current investigations into using RABV as a vector for recombi-
nant antigens against other infectious diseases, such as Ebola, AIDS,
SARS and anthrax [14–17]. A common strategy for RABV engineer-
ing is to incorporate a gene of interest into an extra transcriptional
unit created in the RABV genome. For a small peptide like GnRH,
the traditional strategy may not be successful, because GnRH is a
small self-antigen. Our previous in vitro study demonstrated we
were able to insert GnRH coding sequence into selected locations
in the RABV G gene [18]. Here, we further focused on the RABV G
gene in accepting the copy number of GnRH, and demonstrated
although RABV G recombinant protein with up to 4 copies of GnRH
was well expressed, the recombinant virus was recovered only
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the G protein, indicating a possible insertion cap in making a full
infectious clone. Our investigation provides insight into the RABV
G as a carrier for small peptide vaccine studies. Following our
previous study, we selected ERAg3p/2GnRH and tested the con-
struct in mice. The vaccine induced P80% infertility after three
doses without any adjuvant, in live (8 of 10 mice infertility) or
inactivated (13 of 14 mice infertility) formulations; while the preg-
nancy rate was 100% (10 of 10 mice) in the controls. This initial
success of immunocontraception in mice is promising, and we
are now optimizing the vaccine formulation by using adjuvants
and exploring novel delivery methods to reduce the immunization
dosage.Materials and methods
RABV G gene and mutagenesis
The RABV ERA G gene was cloned into the pcDNA3.1/Zeo ()
plasmid (Invitrogen, Carlsbad, CA), creating pcDNA-G. The GnRH
coding sequence was introduced into the G gene as described
[19,20]. To evaluate the G gene in accepting multiple copies of
GnRH, the GnRH coding sequences were increased gradually from
2 to 20 copies, resulting in constructs of pcDNAG-2GnRH (G gene
with 2 inserted GnRH copies), pcDNAG-3GnRH, pcDNAG-4GnRH,
pcDNAG-5GnRH, pcDNAG-6GnRH, pcDNAG-7GnRH, pcDNAG-
8GnRH, pcDNAG-9GnRH, pcDNAG-10GnRH, pcDNAG-13GnRH
and pcDNAG-20GnRH.
Plasmid transfection, RABV G and GnRH expression
The BSR cells (a clone of baby hamster kidney cell line) were
grown in Dulbecco’s minimal essential medium (DMEM) supple-
mentedwith 10% fetal bovine serum (Atlanta Biologicals, Lawrence-
ville, GA). The day before transfection, the cells were split at
50,000 cells/ml, and 2 ml of cell suspensions were seeded into each
well of a 6-well-plate (Thermo Fisher Scientiﬁc, Waltham, MA).
Twenty-four hours after incubation, each well of BSR cells at 50%
conﬂuency were transfected with the above 11 individual pcD-
NAG-GnRH constructs at 1 lg/well, using the TransIT-LT1 reagent,
according to the manufacturer’s instructions (Mirusbio, Madison,
WI). Forty-eight hours post-transfection, the cells were ﬁxed using
10% PBS-buffered formalin SF100-4 (Thermo Fisher Scientiﬁc, Wal-
tham,MA), and reactedwithapanel ofmouseanti-RABVGmonoclo-
nal antibodies (CDC, Atlanta, GA) at 37 C for 30 min. The cells were
washed 3 times in PBS buffer (pH 7.2, 0.01 M), and stained with an
anti-mouse IgG AB-FITC conjugate (Millipore Light Diagnostics™,
Temecula, CA) at 37 C for 30 min. After 3 intensive washes in PBS
(pH 7.2, 0.01 M), the cells were dried at room temperature and visu-
alizedunderﬂuorescentmicroscopy. Similarly, theGnRHexpression
was analyzed by reacting with the rabbit anti-GnRH antibodies at a
1:200 dilution (USDA Wildlife Services). The conjugate goat anti-
rabbit IgG (H + L)-FITC was used at a 1:200 dilution (Vector Labora-
tories Inc., Burlingame, CA).
Virus recovery, growth dynamics, puriﬁcation of virus and
recombinant G-2GnRH protein
After RABV G and GnRH expression were veriﬁed in plasmid-
transfected cells, the hybrid genes G-2GnRH, G-3GnRH, and
G-4GnRH from the pcDNA plasmids were cloned, respectively,
back into the RABV ERA genome. An established protocol was
followed for virus recovery [20]. We measured the growth dynam-
ics between ERAg3p and ERAg3p/2GnRH viruses [18]. Similar to
Method 2.2 above, 48 h after virus infection, the G and GnRHexpression was analyzed. We puriﬁed the RABV ERAg3p virus,
the G protein from ERAg3p, the ERAg3p/2GnRH virus, and the G-
2GnRH protein from ERAg3p/2GnRH virus, as described [21,22].Co-expression of G and GnRH on the virus surface
Forty-eight hours after ERAg3p/2GnRH virus infection, BSR cells
were ﬁxed using 10% buffered formalin phosphate SF100-4 (Ther-
mo Fisher Scientiﬁc, Waltham, MA). The cells were blocked using
10 mM glycine PBS (pH 7.2, 0,01 M) for 1 h, reacted with a mixture
of mouse anti-G mAb 507-1 at 1:200 dilution (CDC, Atlanta, GA)
and rabbit anti-GnRH antibodies at 1:200 (USDAWildlife Services),
followed by simultaneous staining with a mixture of FITC-labeled
goat anti-mouse and Rhodamine-labeled goat anti-rabbit second-
ary antibodies at a 1:200 dilution (KPL Inc., Gaithersburg, MD).
The RABV G and GnRH staining in virus-infected cells were viewed
under immunoﬂuorescence microscopy.SDS–PAGE and western blotting
The puriﬁed RABV ERAg3p, ERAg3p/2GnRH virions, G and
G-2GnRH proteins were subject to SDS–PAGE, followed by
western-blotting. In brief, 10 ll of the materials were loaded to
gels, and were transferred to a PVDF membrane (Sigma–Aldrich,
St. Louis, MO) after SDS–PAGE was completed. The membrane
was blocked in 5% nonfat milk (PBS, pH 7.2, 0.01 M) overnight at
4 C. For detection of RABV G protein, a linear epitope mAb
63-80-6 (CDC, Atlanta, GA) against the G was added to the
membrane. After 30 min incubation at room temperature, the
membrane was washed 3 times in PBS-T (pH 7.2, 0.01 M, plus
0.05% Tween-20). The anti-mouse IgG-HRP conjugate at 1:1000
was added (Sigma–Aldrich, St. Louis, MO), and the bands were
visualized in tetramethylbenzidine substrate solution (USB,
Cleveland, OH). For detection of GnRH, a similar procedure was
followed by using rabbit anti-GnRH antibodies at a 1:500 dilution
(USDA Wildlife Services) and anti-rabbit IgG-HRP conjugate at a
1:1000 dilution (Sigma–Aldrich, St. Louis, MO).Mouse vaccination using the ERAg3p/2GnRH virus
The animal protocol #2132FRAMOUC-A3 was established in
compliance with CDC Institutional Animal Care and Use
Committee. Two month-old CBA/CaJ mice (Charles River
Laboratory, Wilmington, MA) were divided into 4 groups and
immunized intramuscularly (i.m.) in the quadriceps muscle: group
A, control mice: the placebo injection was 50 ll of 107 focus
forming units (ffu) of ERAg3p virus (10 cages of paired female
and male mice, with each cage having 1 male and 1 female); group
B, 1 dose of 50 ll at 107 ffu of live ERAg3p/2GnRH virus for both
sexes (15 cages of paired female and male mice, with each cage
having 1 male and 1 female); group C, 3 doses of live ERAg3p/
2GnRH vaccine for one sex (10 cages: 5 pairs with 1 vaccinated
female and 1 unvaccinated male, and 5 pairs with 1 unvaccinated
female and 1 vaccinated male; one pair per cage); group D, 3 doses
of inactivated ERAg3p/2GnRH recombinant vaccine (gamma
irradiated, CDC, Atlanta, GA) for both sexes (14 cages of paired
female and male mice, with each cage having 1 male and 1 female).
In the 3-dose groups, the animals received 2 additional boosts
at 3-week intervals. Two weeks after immunization or the last
boost, mice were matched for breeding. Mice were observed twice
daily. Observation was terminated 1 year after the breeding test or
when mice became pregnant. At termination, mice were
euthanized according to the protocol #2132FRAMOUC-A3.
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When the animal breeding tests were terminated or mice were
euthanized, a few animal representatives were subject to necropsy
for comparison of their reproductive organs: epididymis, testis and
uterus. The testicular smears were made from fresh tissues, ob-
served and recorded under regular light microscopy. The reproduc-
tive organs of male and female mice were collected, and soaked in
10% formalin for no less than 72 h before processing. A standard
histochemisty and H & E staining protocol was followed (http://
www.cdc.gov/rabies/diagnosis/immunohistochemistry.html).
Statistics
The p-value was calculated using the two-tailed Fisher Exact
test (http://www.danielsoper.com; statistics calculators, version
3.0).Results
Multiple copies of GnRH gene can be incorporated into RABV G, but 4
copies of GnRH is the expression limit
Previous studies supported a positive correlation between
GnRH copies and efﬁcacy of immunocontraception [23,24]. To test
the ability of RABV G gene in accepting an ideal copy number of
GnRH, we constructed 11 G-GnRH hybrid genes, with 2, 3, 4, 5, 6,
7, 8, 9, 10, 13, or 20 GnRH copies (Fig 1a). Multiple tandem copies
of GnRH coding sequence were readily introduced into the RABV G
gene by mutagenesis. However, in subsequent transfections, we
did not observe abundant RABV G or GnRH protein expression in
constructs other than pcDNAG-2GnRH, pcDNAG-3GnRH and pcD-
NAG-4GnRH. The staining of RABV G and GnRH was gradually
diminished when high copies of GnRH were inserted (Fig. 1b),
and no staining was obviously visible when 6 or more copies of
GnRH were introduced (data not shown). Based on these observa-
tions, we conclude RABV G can accept multiple copies of GnRH, but
40 extra amino acids (4 copies of GnRH) is the insertion limit for a
successful expression.
The success expression of RABV G and GnRH in the hybrid gene does
not mirror its success in virus recovery
The expression of RABV G and GnRH in the hybrid gene G-
3GnRH and G-4GnRH would be ideal for immunocontraception
studies. Thus we cloned the G-3GnRH and G-4GnRH genes, respec-
tively, back into the ERAg3p genome. To our surprise, neither con-
struct generated an infectious clone (data not shown). The full-
length viral cDNA sequence was rechecked, and the transfection
tests were repeated in triplicate, with the same result. This obser-
vation showed success expression of a recombinant G protein does
not always correlate with a success in the subsequent recombinant
virus recovery, highlighting the importance of using full infectious
clones for protein function studies.
The ERAg3p/2GnRH is an ideal RABV-vectored GnRH recombinant
Our previous investigation attempted to locate the site in the G
for GnRH incorporation [18], but did not focus on the number of
GnRH copies that could be incorporated. This current investigation
clearly demonstrated 2 copies of GnRH was the insertion cap that
can be added to the G and still recover a full infectious clone. To
characterize the recombinant G-2GnRH protein, both G and G-
2GnRH proteins were extracted from puriﬁed virions, and were
analyzed by western blotting. The molecular mass of G-2GnRHwas approximately 68 kDa, and the GnRH peptide was clearly de-
tected in both puriﬁed G-2GnRH protein and ERAg3p/2GnRH viri-
ons, but neither in the puriﬁed G nor in ERAg3p (Fig. 2a). The
virus growth dynamics were comparable between the ERAg3p
and ERAg3p/2GnRH viruses, indicating fusion of 2 copies of GnRH
to the amino terminus of G did not impact incorporation of G-
2GnRH into viral particles (Fig. 2b). This was also conﬁrmed by
demonstration of intracellular transport of the G-2GnRH protein
in virus-infected cells. The ERAg3p/2GnRH showed a similar spread
pattern to the ERAg3p virus, and the GnRH protein was presented
on the cell surface, and merged to the location where the G protein
was present (Fig. 2c).ERAg3p/2GnRH virus induced immunocontraception in mice
Our previous study did not test any immunocontraceptive
viruses in animals, and only safety and efﬁcacy of ERAg3p virus
against rabies was completed in mice [18,25]. Here a single chal-
lenging question for us is: does ERAg3p/2GnRH virus induce
immunocontraception in an animal model? Our expectation is
not to test if ERAg3p/2GnRH sterilizes animals by a single dose,
but to test the biological utility of the recombinant.
By the end of the study (12 months), the immunocontracep-
tion was maintained in the 3-dose groups. To summarize
(Fig. 3a), in the control group A, 10 of 10 pairings became pregnant
(100%) within 3–4 weeks after breeding. In group B, receiving 1
dose of live recombinant vaccine, 15 of 15 pairings became preg-
nant within 3–5 weeks (100%). Group C was subdivided into group
Cf (immunized female only) and group Cm (immunized male only),
and 1 of 5 pairings in group Cf, and 1 of 5 pairings in group Cm be-
came pregnant. To test if immunocontraception would be im-
proved by immunizing both animal sexes, the inactivated
ERAg3p/2GnRH in 3 doses was administrated in group D. Indeed,
the pregnancy rate in group D was reduced to 7% (1 of 14 pairs).
The pregnancy reduction in groups C (80%) and D (93%) was signif-
icant in comparison to groups A (0%) and B (0%) (p < 0.001).
During the observation period, no mice presented any signs of
rabies or illness. The pregnancy usually occurred within 3–5 weeks
after breeding, and no further pregnancy was observed 3 months
thereafter. Preliminary histochemistry examination of reproduc-
tive organs from a few representative animals presented signiﬁ-
cant changes in the organs (Fig. 3b and c).Discussion
Our previous in vitro study demonstrated RABV can be a vector
for GnRH expression [18]. To incorporate more copies of GnRH into
the RABV G, a positive correlation between GnRH copies and efﬁ-
cacy of immunocontraception, we further investigated the RABV
G in accepting various copy numbers of GnRH. And we found the
ERAg3p/2GnRH was the best candidate so far and then tested the
recombinant virus in mice. As a master hormone, GnRH is an effec-
tive target in both sexes. Decades of research using GnRH for ani-
mal immunocontraception and hormonal control have led to at
least two licensed products: Improvac and GonaCon™. Improvac
is a diphtheria toxoid (DT)-GnRH conjugate used for suppression
of boar taint in meat [26,27], and has been licensed in more than
20 countries [28]. GonaCon™ is also a conjugated product, with
the GnRH linked to keyhole limpet hemocyanin (KLH), and has
been licensed conditionally by the U.S. Environmental Protection
Agency for immunocontraception in deer [29]. The encouraging
outcomes of Improvac and GonaCon™ motivated us to investigate
the potential of a RABV-vectored immunocontraceptive biologic.
Until now, no virus-vectored GnRH recombinant has been success-
fully demonstrated for immunocontraception. Instead of using
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Tandem copies of GnRH were verified by sequencing after mutagenesis, and the
Sma1 site is located between the neighboring GnRH coding sequences. 
Fig. 1. GnRH expression after recombinant plasmid transfection. (a) Introduction of multiple GnRH copies into RABV G. (b) G protein and GnRH expressions (magniﬁcation
200). Although G protein and GnRH were expressed in plasmids pcDNAG-3GnRH- and pcDNAG-4GnRH-transfected cells, the staining decreased when the GnRH copies
increased from 3 to 5.
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proteins [30–34], we ‘‘conjugated’’ the GnRH to RABV G. The RABV
G is the only outer membrane protein responsible for virus attach-
ment and induction of virus neutralizing antibodies. It has multiple
T and B cell epitopes with a molecular mass of 66 kDa, close to DT
(60 kDa). The ‘‘conjugated’’ RABV G-GnRH protein is assembled
into self-replicating RABV particles. Due to the unavailability of
Improvac (not licensed in the U.S.) and GonaCon™ (not commer-
cially available), direct comparison of these two vaccines withERAg3p/2GnRH was not possible in the mouse model. For deer
immunocontraception, GonaCon™ at 850–1000 lg ml1 is sug-
gested, and having 300 GnRH molecules coupled to the surface
of KLH [35]. In RABV, the G copy number per virion has been calcu-
lated to be 1500, leading to 3000 copies of GnRH per ERAg3p/
2GnRH virion [36,37]. For each mouse, 107 ffu of virus was admin-
istrated i.m., equivalent to the recommended doses of GonaCon™
and Improvac (Table S1). This dose also provided effective protec-
tion against RABV challenge in a prior research [25]. Our calculated
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Fig. 2. Characterization of recombinant G-2GnRH protein. (a) The recombinant G-2GnRH protein was analyzed by western blotting. Lane 1: puriﬁed RABV ERAg3p virions.
Lane 2 and 3: puriﬁed recombinant RABV ERAg3p/2GnRH virions, and lane 3 about half the loading of lane 2. Lane 4: puriﬁed G protein. Lane 5: puriﬁed recombinant G-
2GnRH protein. The variance in the density of the bands was due to loading. (b) Virus growth dynamics between RABV ERAg3p and ERAg3p/2GnRH. (c) Recombinant G-
2GnRH protein in RABV virus-infected cells (magniﬁcation 200). The recombinant G-2GnRH protein was transported to the RABV virus-infected cell surface (FITC staining),
as was GnRH peptide (Rhodamine staining). The merged image presented an overlapping staining of GnRH and recombinant G protein in the virus-infected cells. 40 ,6-
Diamidino-2-phenylindole (DAPI) served as a Rhodamine staining control.
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ception in the 3-dose groups as either a live or inactivated product
(Fig 3).Our RABV recombinant as a peptide hormone control vaccine is
very different from the previous pseudotyped RABV-vectored
vaccines [17]. The pseudotyping approach uses a glycoprotein of
 Pregnancy rate in mice after immunization  
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Fig. 3. Immunocontraception of rabies virus ERAg3p/2GnRH in mice. (a) Mouse pregnancy rate was 100% in group A (controls, receiving ERAg3p virus) and B (1 dose of live
recombinant vaccine), 20% in group C (3 doses of live recombinant vaccine), and 7% in group D (3 doses of inactivated recombinant vaccine for both animal sexes). (b) The
testicular tissue smears in males control group A presented normal sperm numbers. Reduced sperms or no sperm were observed in immunized mouse groups C and D
(magniﬁcation 200). (c) Histochemistry changes in immunized mice (magniﬁcation 200). In control group A males, coils of the epididymis were lined with columnar
epithelium and ﬁlled with sperms; the seminiferous tubules in testis were lined with typical multilayered germinal epithelium and the lumen contained sperms. In mouse
groups C and D, the coils of the epididymis were lined with cuboidal epithelium, and no sperm was found in the coils; the tubules in the testis were atopic, and were lined
with a single layer of degenerating epithelium. In the uterus of control females, the endometrium was normal, and was comprised of columnar epithelium and connective
tissues. In the uterus of treated females in groups C and D, the endometrium was in a reproductively quiescent or ‘‘still state.’’
16 X. Wu et al. / Trials in Vaccinology 3 (2014) 11–18interest to replace the ecto-domain of RABV G, creating a RABV
skeleton, but coated with an unrelated glycoprotein. Our approach
by identifying an ideal site and incorporating optimal copies of
GnRH into RABV G is novel and successful for immunocontracep-
tive vaccine studies. Our investigation also provides insight intoRABV G as a carrier for small peptide vaccines. Large insertions ren-
der the G protein nonfunctional, as evidenced in the G-3GnRH and
G-4GnRH hybrids. Detailed investigation into the mechanism
would be interesting. However, our speciﬁc intention was to test
the immunocontraception efﬁcacy of ERAg3p/2GnRH in an animal
X. Wu et al. / Trials in Vaccinology 3 (2014) 11–18 17model. The resulting 80% (group C) and 93% (group D) immunocon-
traception demonstrated the viability of using RABV ERAg3p/
2GnRH as a dual vaccine for consideration in rabies prevention
and animal population management. Sustainable vaccine release
after injection could be the key in inducing a long-lasting GnRH
antibody response to suppress reproduction in animals. The pro-
gress of ERAg3p/2GnRH in mice sterilization is promising, and
the 3 dose administration could be reduced by improving vaccine
formulations and delivery methods. Further studies are being
scheduled in the target animal species.
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